The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index; 14 of the 40 sources its claims cite were checked for support.
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Open accessAbstract
BACKGROUND: Daratumumab showed promising efficacy alone and with lenalidomide and dexamethasone in a phase 1-2 study involving patients with relapsed or refractory multiple myeloma. METHODS: In this phase 3 trial, we randomly assigned 569 patients with multiple myeloma who had received one or more previous lines of therapy to receive lenalidomide and dexamethasone either alone (control group) or in combination with daratumumab (daratumumab group). The primary end point was progression-free survival. RESULTS: white cells), as compared with 4.6% of those in the control group (P<0.001); results below the threshold for minimal residual disease were associated with improved outcomes. The most common adverse events of grade 3 or 4 during treatment were neutropenia (in 51.9% of the patients in the daratumumab group vs. 37.0% of those in the control group), thrombocytopenia (in 12.7% vs. 13.5%), and anemia (in 12.4% vs. 19.6%). Daratumumab-associated infusion-related reactions occurred in 47.7% of the patients and were mostly of grade 1 or 2. CONCLUSIONS: The addition of daratumumab to lenalidomide and dexamethasone significantly lengthened progression-free survival among patients with relapsed or refractory multiple myeloma. Daratumumab was associated with infusion-related reactions and a higher rate of neutropenia than the control therapy. (Funded by Janssen Research and Development; POLLUX ClinicalTrials.gov number, NCT02076009 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
53 Own result · 10 Own method · 6 No full text of the sources · 5 Sources not found · 4 Supported · 4 Partly supported · 4 Own interpretation · 2 Supported so far · 1 Not checked yet · accuracy not yet measured
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, this category of minimal residual disease status has not been examined to date in patients with relapsed or refractory multiple myeloma, in part because of limited availability of data showing a correlation between depth of response and survival outcomes in patients at this stage of the disease.7”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Abstract
What the sources say
- Partly supportedcites [7] sourceExperimental — accuracy not yet measured
The “Relapsed and/or refractory” section (page unavailable) says data linking depth of response to outcomes are limited, supporting the citing sentence’s rationale. The “Redefining CR” section discusses minimal residual disease (MRD) studies in newly diagnosed patients, but does not state that MRD status had never been examined in relapsed or refractory patients. The relapsed-setting section’s “MR” means minimal response, not minimal residual disease. (LLM, conf=0.78)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“As in our trial (POLLUX), the addition of daratumumab to a standard-of-care regimen of bortezomib and dexamethasone in the CASTOR trial was associated with a significantly lower risk of disease progression or death.18”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Discussion
What the sources say
- Supportedcites [18] source
The Trial Treatments section (p. 3) confirms that CASTOR compared daratumumab plus bortezomib and dexamethasone with bortezomib and dexamethasone alone. The Discussion (p. 11) reports significantly longer progression-free survival and a 61.4% lower risk of disease progression or death in the daratumumab group. (LLM, conf=0.94)
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Daratumumab with lenalidomide and dexamethasone was associated with clinically manageable adverse events that were consistent with the known toxic effects of lenalidomide and dexamethasone 27,28,30,31 and of daratumumab.9,10”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Patients who have very good partial responses
What the sources say
- Not checked — no full text of the sourcecites [27] source
- Supportedcites [28] source
The Safety section identifies thrombocytopenia, gastrointestinal events, and rash as adverse events observed with lenalidomide-dexamethasone, and describes management of gastrointestinal events with supportive therapy and dose adjustment. This supports the part of the sentence attributed to this paper: the known toxic effects of lenalidomide-dexamethasone. The daratumumab-specific part has separate citations and is not attributed to this source. (LLM, conf=0.90)
- Supportedcites [30] source
This citation is attached to the known toxic effects of lenalidomide and dexamethasone, not to the daratumumab-specific part of the sentence. The Randomization and Study Treatment section identifies a lenalidomide–dexamethasone control group, and the Safety section and Table 3 report its adverse events. The paper does not assess the daratumumab combination. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [31] source
- Not checked — no full text of the sourcecites [9] source
- Supportedcites [10] source
This source is cited for the known toxic effects of daratumumab, not for the safety of the three-drug combination. The Safety section (p. 5) reports that most adverse events with daratumumab were grade 1 or 2, and the Discussion (p. 11) describes an acceptable safety profile and mostly mild infusion-related reactions. (LLM, conf=0.89)
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Similar results were observed in the intentionto-treat population (Table S3 in the Supplementary Appendix).”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Efficacy
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Consistent with the higher rates of deeper responses in the daratumumab group, the rate of results below the threshold for minimal residual disease was significantly higher in the daratumumab group than in the control group (by 3 to 5 times) at all evaluated thresholds (1 tumor cell per 10 4 , 10 5 , and 10 6 white cells) (Fig. S4 in the Supplementary Appendix).”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Efficacy
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“At the interim analysis, a total of 75 deaths had been observed (30 patients in the daratumumab group and 45 in the control group) (Table S4 in the Supplementary Appendix).”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Efficacy
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A significantly higher rate of overall response was observed in the daratumumab group than in the control group (92.9% vs. 76.4%,P<0.001), as was a higher rate of complete response or better (43.1% vs. 19.2%,P<0.001).”
- Also stated in: § Efficacy · plain
“the rate of complete response or better (43.1% vs. 19.2%,P<0.001).”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Abstract
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Efficacy · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Progression-free survival was similarly prolonged in the daratumumab group among patients who had previous exposure to lenalidomide and those who had no previous exposure, as compared with the control group (Fig. S3 in the Supplementary Appendix).”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Efficacy
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The median progression-free survival was not reached (95% CI, could not be estimated) in the daratumumab group, as compared with 18.4 months (95% CI, 13.9 to could not be estimated) in the control group.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Efficacy
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Among patients with a partial response or better, the rate of progression-free survival at 12 months was 87.8% (95% CI, 83.1 to 91.3) in the daratumumab group versus 73.6% (95% CI, 67.0 to 79.1) in the control group.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Efficacy
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Daratumumab, a human IgGκ monoclonal antibody that targets CD38, 8 has shown substantial single-agent efficacy and a manageable safety profile in phase 1-2 studies involving patients with heavily pretreated relapsed or refractory multiple myeloma, with reported overall response rates of 29% and 36%.9,10”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Abstract
What the sources say
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Daratumumab, a human IgGκ monoclonal antibody that targets CD38, 8 has shown substantial single-agent efficacy and a manageable safety profile in phase 1-2 studies involving patients with heavily pretreated relapsed or refractory multiple myeloma, with reported overall response rates of 29% and 36%.9,10”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Abstract
What the sources say
- Supportedcites [8] source
The Ab generation section states that all antibodies described, including daratumumab, were human IgG1, κ antibodies. The Discussion identifies daratumumab as a human IgG1 antibody that binds CD38. The later phase 1–2 efficacy claims carry separate citations and are not attributed to this source. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The primary end point was progression-free survival, with progression determined with the use of a validated computer algorithm that combined laboratory results (e.g., M-protein level) and applicable imaging and generated the outcome according to IMWG criteria (see the Supplementary Appendix).20,21 This algorithm previously showed very strong concordance with independent reviews in a phase 2 study”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > End Points and Assessments
What the sources say
- Not checked — no full text of the sourcecites [20] source
- Partly supportedcites [21] sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 1 unverifiable. Expand the claim to see per-atom verdicts.
- Not checked — no full text of the sourcecites [9] source
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
Every source the paper cites for this claim was checked and supports it.
In the paper
“A phase 3 trial of bortezomib and dexamethasone, with or without daratumumab, met its primary end point at the interim analysis and showed a significantly higher rate of progression-free survival, with a 61% lower risk of progression or death in the daratumumab group than in the control group.18”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Abstract
What the sources say
- Supportedcites [18] source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“After the implementation of guidelines from other studies of daratumumab regarding the management of infusion-related reactions, infusion-related reactions were consistent with daratumumab monotherapy 9,10 and combination therapy, 18,19,32 were mostly of grade 1 or 2, and usually occurred during the first infusion.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Patients who have very good partial responses
What the sources say
- Not checked — no full text of the sourcecites [9] source
- Supportedcites [10] source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
- Partly supportedcites [18] sourceExperimental — accuracy not yet measured
Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
- Not matchedcites [19] Plesner T, Blood
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Could not verifycites [32] Chari A, 2015, Blood sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 2 unverifiable. Expand the claim to see per-atom verdicts.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Response was assessed according to the Uniform Criteria Consensus recommendations of the International Myeloma Working Group.20,21”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Efficacy
What the sources say
- Not checked — no full text of the sourcecites [20] source
- Supportedcites [21] source
The Response criteria section recommends using the IMWG uniform response criteria in clinical trials and says the panel endorsed their response definitions. The citation therefore supports the identification of the criteria used; it does not independently document how the citing study assessed response. (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Daratumumab interferes with laboratory-based bloodcompatibility tests, including indirect Coombs' test, because of binding to CD38 on red cells.26”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Table 3. Most Common Adverse Events during Treatment in the Safety Population.*
What the sources say
- Supportedcites [26] source
The Discussion says daratumumab interferes with blood compatibility testing because it binds directly to CD38 on red cells. The “DARA causes plasma panreactivity in vitro” section reports panreactivity at the antihuman globulin phase, supporting the reference to the indirect Coombs test. (LLM, conf=0.93)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Daratumumab was associated with infusion-related reactions and a higher rate of neutropenia than the control therapy.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Abstract
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Daratumumab-associated infusion-related reactions occurred in 47.7% of the patients and were mostly of grade 1 or 2.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Abstract
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Similarly, in the time-toevent analysis of disease progression, a total of 148 events (in 44 patients [15.4%] in the daratumumab group vs. 104 [36.7%] in the control group) were observed (hazard ratio, 0.34; 95% CI, 0.23 to 0.48; P<0.001).”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Efficacy
plaincorrelationaln = 44- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The percentage of patients with adverse events leading to the discontinuation of treatment was similar in the two groups: 6.7% in the daratumumab group and 7.8% in the control group.”
- Also stated in: § Patients who have very good partial responses · plain
“The rates of treatment discontinuation owing to adverse events were low and similar in the two groups.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Table 3. Most Common Adverse Events during Treatment in the Safety Population.*
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Also stated in: § Patients who have very good partial responses · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The treatment effect of daratumumab was consistent regardless of previous exposure to lenalidomide (a limitation being the relatively small number of patients with previous exposure to lenalidomide) and across all subgroups, including patients 65 years of age or older, those with disease that was refractory to proteasome inhibitors or the most recent line of therapy, those with International Stag”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Discussion
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Although higher rates of neutropenia and infusion-related reactions (primarily during the first infusion) were observed with this combination than with lenalidomide and dexamethasone alone, these events did not result in higher rates of treatment discontinuation or death.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Patients who have very good partial responses
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“After continued treatment, responses deepened, with a rate of complete response or better that was twice as high with daratumumab as with the backbone regimen alone.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Discussion
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These reactions were mostly of grade 1 or 2; a total of 15 patients (5.3%) had grade 3 infusion reactions, and no patient had an event of grade 4 or 5.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Table 3. Most Common Adverse Events during Treatment in the Safety Population.*
plainn = 15- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Overall response No. with response 261 211 -Rate -% (95% CI) 92.9 (89.2-95.6)76.4 (71.0-81.3)<0.001”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Efficacy
plainn = 281 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Serious adverse events were reported in 48.8% of the patients in the daratumumab group and in 42.0% of those in the control group, among which pneumonia was the most common (in 8.1% of the patients in the daratumumab group and in 8.5% of those in the control group).”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Table 3. Most Common Adverse Events during Treatment in the Safety Population.*
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The rate of infection of grade 3 or 4 was also slightly higher in the daratumumab group than in the control group (28.3% and 22.8%, respectively); the most common infection of grade 3 or 4 was pneumonia, which occurred at similar rates in the two groups.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Table 3. Most Common Adverse Events during Treatment in the Safety Population.*
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The most common adverse events leading to death were acute kidney injury (in 0.4% of the patients in the daratumumab group and in 1.1% in the control group), septic shock (in 1.1% and 0.4%, respectively), and pneumonia (in 0.7% in each group).”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Table 3. Most Common Adverse Events during Treatment in the Safety Population.*
plainn = 11- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“incidences of grade 3 or 4 diarrhea, fatigue, nausea, and dyspnea were slightly higher in the daratumumab group than in the control group.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Table 3. Most Common Adverse Events during Treatment in the Safety Population.*
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Stringent complete response § 51 (18.1) 20 (7.2) -”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Efficacy
plainn = 281- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The incidence of daratumumab infusionrelated reactions of any grade was 47.7%, with 92% of the reactions occurring during the first infusion.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Table 3. Most Common Adverse Events during Treatment in the Safety Population.*
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The most common adverse events (in ≥1% of the patients in either group) that led to the discontinuation of treatment included pneumonia (in 1.1% of the patients in the daratumumab group and in 0.7% of those in the control group), pulmonary embolism (in 1.1% in the control group), and deterioration in general physical health (in 1.1% in the daratumumab group).”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Table 3. Most Common Adverse Events during Treatment in the Safety Population.*
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Despite higher rates of neutropenia in the daratumumab group, the rate of infection of grade 3 or 4 was only slightly higher in the daratumumab group than in the control group (28% vs. 23%).”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Patients who have very good partial responses
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“As in the CASTOR trial, 18 the addition of daratumumab to the backbone regimen in our trial resulted in a significantly higher rate of overall response, deeper responses, and longer duration of response.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Discussion
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The most common infusion-related reactions were cough (in 8.5% of the patients), dyspnea (in 8.5%), and vomiting (in 5.7%) (Table S5 in the Supplementary Appendix).”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Table 3. Most Common Adverse Events during Treatment in the Safety Population.*
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“A phase 1-2 study of daratumumab, lena-lidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma showed that this combination provided therapeutic benefits, no dose-limiting toxic effects, and an 81% rate of overall response, including a 25% rate of stringent complete response”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Abstract
What the sources say
- Not matchedcites [19] Plesner T, Blood
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Not matched
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The group-sequential design had one planned interim analysis to evaluate the primary end point.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Statistical Analysis
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“he incorporation of proteasome inhibitors and immunomodulatory drugs into the standard of care has improved outcomes in patients with multiple myeloma over the past 10 years, [1][2][3]”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Abstract
What the sources say
- Not matchedcites [1][2][3]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
- Not matched
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The trial was approved by the independent ethics committee or institutional review board at each site before the initiation of the trial.Patients provided written informed consent, and the trial was conducted in accordance with the principles of the Declaration of Helsinki and current International Conference on Harmonisation Good Clinical Practice guidelines.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Trial Design
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“An independent data and safety monitoring committee was established to periodically review unblinded safety data.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > End Points and Assessments
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“At 18 months, the rate of progression-free survival was 72%, and the rate of overall survival was 90%.19”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Abstract
What the sources say
- Not matchedcites [19] Plesner T, Blood
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
- Not matched
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The most common reasons for the discontinuation of treatment were progressive disease (in 14.1% of the patients in the daratumumab group vs. 34.2% of those in the control group) and adverse events (in 6.7% vs. 8.2%) (Fig. S2 in the Supplementary Appendix).”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Patients and Treatment
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“We calculated that approximately 560 patients with 295 events (disease progression or death) would be needed to provide the trial with 85% power to detect a 30% lower risk of disease progression or death (hazard ratio, 0.70), using a log-rank test, with an overall two-sided significance level of 0.05.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Statistical Analysis
plainn = 560- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This suggests that results below the threshold for minimal residual disease also should be a treatment goal in the context of relapsed or refractory disease.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Patients who have very good partial responses
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: fails — It may be too vague to check against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may be too vague to check against evidence.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Figure 2. Prespecified Subgroup Analyses.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Patients who have very good partial responses
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Shown are the results of the Kaplan-Meier analysis of progression-free survival among patients in the intention-totreat population, which included all patients who underwent randomization.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Patients who have very good partial responses
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
The paper relies on this without support.
Relapse can occur even after standard complete remission in the context of first-line therapy.
“Relapse can occur even after standard complete remission in the context of first-line therapy, and studies are therefore evaluating deeper responses in a category termed “minimal residual disease-negative””
The paper relies on this without support.
The combination of lenalidomide and dexamethasone is an appropriate standard control regimen for patients with relapsed or refractory multiple myeloma who have received one or more previous lines of therapy.
“we randomly assigned 569 patients with multiple myeloma who had received one or more previous lines of therapy to receive lenalidomide and dexamethasone either alone (control group) or in combination with daratumumab (daratumumab group).”
The paper relies on this without support.
The open-label design does not bias the assessment of progression-free survival.
“In this randomized, open-label, multicenter, phase 3 trial, we assigned patients who had relapsed or refractory multiple myeloma and had received one or more lines of previous therapy to receive either daratumumab, lenalidomide, and dexamethasone (daratumumab group) or lenalidomide and dexamethasone (control group).”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The recently approved monoclonal antibody, daratumumab, which targets CD38 (a receptor highly expressed on myeloma cells), has become a favorite for later line induction regimens [35,36].”
From Epidemiology, Staging, and Management of Multiple Myeloma (2021) · cites this paper as [36]
Experimental — accuracy not yet measuredIn the citing paper
“Response rates to single-agent lenalidomide have consistently been surpassed by those achieved with doublet or triplet combinations, which has been taken as evidence for synergistic activity of this agent with other anti-myeloma agents48.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [48]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Patients and Treatment
“The most common reasons for the discontinuation of treatment were progressive disease (in 14.1% of the patients in the daratumumab group vs. 34.2% of those in the control group) and adverse events (in 6.7% vs. 8.2%)”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Table 3. Most Common Adverse Events during Treatment in the Safety Population.*
“The percentage of patients with adverse events leading to the discontinuation of treatment was similar in the two groups: 6.7% in the daratumumab group and 7.8% in the control group.”
Citations
Cites
Kumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.-V., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30206-6 · Cited by 3,061
Self-citationInternational uniform response criteria for multiple myeloma
Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632
Self-citationDiscrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Improved survival in multiple myeloma and the impact of novel therapies
Kumar, S. K., Rajkumar, S. V., Dispenzieri, A. A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Zeldenrust, S. R., Dingli, D., Russell, S. J., Lust, J. A., et al. (2007) · Blood · doi:10.1182/blood-2007-10-116129 · Cited by 2,241
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Palumbo, A., Chanan-Khan, A., Weisel, K., Nooka, A. K., Masszi, T., Beksac, M., Spicka, I., Hungria, V., Munder, M., Mateos, M. V., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606038 · Cited by 1,522
Self-citationLenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070594 · Cited by 1,450
Self-citationKumar, S. K., Dispenzieri, A. A., Lacy, M. Q., Gertz, M. A., Buadi, F. K., Pandey, S., Kapoor, P., Dingli, D., Hayman, S. R., Leung, N., et al. (2013) · Leukemia · doi:10.1038/leu.2013.313 · Cited by 1,383
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
Stewart, A. K., Rajkumar, S. V., Dimopoulos, M. A., Masszi, T., Špička, I., Oriol, A., Hájek, R., Rosiñol, L., Siegel, D. S., Mihaylov, G. G., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411321 · Cited by 1,332
Self-citationElotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
Lonial, S., Dimopoulos, M., Palumbo, A., White, D., Grosicki, S., Spicka, I., Walter-Croneck, A., Moreau, P., Mateos, M.-V., Magen, H., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505654 · Cited by 1,322
Self-citationTargeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
Lokhorst, H. M., Plesner, T., Laubach, J. P., Nahi, H., Gimsing, P., Hansson, M., Minnema, M. C., Lassen, U., Krejcik, J., Palumbo, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506348 · Cited by 1,117
Self-citation
Research works printed but not linked: 2
- Krejcik J, Blood
- Plesner T, Blood
Cited by
Sorted by citations
Kumar, S. K., Rajkumar, S. V., Kyle, R. A., van Duin, M., Sonneveld, P., Mateos, M., Gay, F., & Anderson, K. C. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.46 · Cited by 1,261
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
Facon, T., Kumar, S., Plesner, T., Orlowski, R. Z., Moreau, P., Bahlis, N., Basu, S., Nahi, H., Hulin, C., Quach, H., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1817249 · Cited by 1,045
Self-citationDiagnosis and Management of Multiple Myeloma
Cowan, A. J., Green, D. J., Kwok, M., Lee, S., Coffey, D. G., Holmberg, L., Tuazon, S. A., Gopal, A. K., & Libby, E. N. (2022) · JAMA · doi:10.1001/jama.2022.0003 · Cited by 1,082
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
Mateos, M., Dimopoulos, M. A., Cavo, M., Suzuki, K., Jakubowiak, A. J., Knop, S. T., Doyen, C., Lúcio, P., Nagy, Z., Kaplan, P., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1714678 · Cited by 1,004
Self-citationMoreau, P., Attal, M., Hulin, C., Arnulf, B., Belhadj, K., Benboubker, L., Béné, M. C., Broijl, A., Caillon, H., Caillot, D., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31240-1 · Cited by 998
Self-citationMultiple myeloma: 2022 update on diagnosis, risk stratification, and management
Rajkumar, S. V. (2022) · American Journal of Hematology · doi:10.1002/ajh.26590 · Cited by 883
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Moreau, P., Miguel, J. F. S., Sonneveld, P., Mateos, M., Zamagni, E., Avet‐Loiseau, H., Hájek, R., Dimopoulos, M. A., Ludwig, H., Einsele, H., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx096 · Cited by 901
“every week (cycles 1–3), every 3 weeks (cycles 4–8), every 4 weeks (cycles 9þ); cycles 1–8: repeated every 21 days; cycles 9þ: repeated every 28 days Lenalidomide/dexamethasone/daratumumab (DRd) [39] Lenalidomide 25 mg orally days 1–21; dexamethasone 40 mg orally weekly; daratumumab 16 mg/kg i.”
BackgroundSelf-citationvan de Donk, N. W. C. J., Pawlyn, C., & Yong, K. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00135-5 · Cited by 935
Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
Dimopoulos, M. A., Moreau, P., Terpos, E., Mateos, M. V., Zweegman, S., Cook, G., Delforge, M., Hájek, R., Schjesvold, F., Cavo, M., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.11.014 · Cited by 900
Self-citationMultiple myeloma: 2020 update on diagnosis, risk‐stratification and management
Rajkumar, S. V. (2020) · American Journal of Hematology · doi:10.1002/ajh.25791 · Cited by 830
“Recent advances in the treatment of relapsed multiple myeloma, including new active agents and results of major randomized trials are discussed below (Table 8).(66,68,69,71-73,75) 137-140 One important consideration is that the lenalidomide-containing regimens listed in Table 8 were tested mainly in patient population…”
BackgroundVoorhees, P. M., Kaufman, J. L., Laubach, J. P., Sborov, D. W., Reeves, B., Rodriguez, C., Chari, A., Silbermann, R. W., Costa, L. J., Anderson, L. D., et al. (2020) · Blood · doi:10.1182/blood.2020005288 · Cited by 717
Self-citationGirmenia, C., Cavo, M., Offidani, M., Scaglione, F., Corso, A., Raimondo, F. D., Musto, P., Petrucci, M. T., & Barosi, G. (2019) · Blood Reviews · doi:10.1016/j.blre.2019.01.001 · Cited by 662
Chen, M., Zhao, Y., Xu, C., Wang, X., Zhang, X., & Mao, B. (2018) · Annals of Hematology · doi:10.1007/s00277-018-3284-y · Cited by 647
Attal, M., Richardson, P. G. G., Rajkumar, S. V., Miguel, J. F. S., Beksaç, M., Špıčka, I., Leleu, X. P., Schjesvold, F. H., Moreau, P., Dimopoulos, M. A., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32556-5 · Cited by 648
Self-citationOutcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.
Gandhi, U. H., Cornell, R. F., Lakshman, A., Gahvari, Z. J., McGehee, E., Jagosky, M. H., Gupta, R., Varnado, W., Fiala, M. A., Chhabra, S., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0435-7 · Cited by 616
Self-citationMultiple myeloma: 2024 update on diagnosis, risk-stratification, and management
Rajkumar, S. V. (2024) · American Journal of Hematology · doi:10.1002/ajh.27422 · Cited by 534
CD38 antibodies in multiple myeloma: back to the future
van de Donk, N. W. C. J., Richardson, P. G. G., & Malavasi, F. (2017) · Blood · doi:10.1182/blood-2017-06-740944 · Cited by 495
Self-citationSubcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities
Bittner, B., Richter, W., & Schmidt, J. (2018) · BioDrugs · doi:10.1007/s40259-018-0295-0 · Cited by 447
Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma
Chari, A., Suvannasankha, A., Fay, J. W., Arnulf, B., Kaufman, J. L., Ifthikharuddin, J. J., Weiss, B. M., Krishnan, A. Y., Lentzsch, S., Comenzo, R. L., et al. (2017) · Blood · doi:10.1182/blood-2017-05-785246 · Cited by 444
“0 (1-13) Prior lines of therapy 1* 3 (3) 2 22 (21) 3 25 (24) .”
BackgroundInfluentialSelf-citationDimopoulos, M., Quach, H., Mateos, M.-V., Landgren, O., Leleu, X., Siegel, D., Weisel, K., Yang, H., Klippel, Z., Zahlten-Kumeli, A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30734-0 · Cited by 430
Self-citationPerrot, A., Lauwers‐Cancès, V., Corre, J., Robillard, N., Hulin, C., Chrétien, M., Dejoie, T., Mahéo, S., Stoppa, A., Pegourié, B., et al. (2018) · Blood · doi:10.1182/blood-2018-06-858613 · Cited by 423
“Among patients with high-risk cytogenetics, MRD negativity was achieved in 17 of 42 patients with t(4;14) (40%), but in only 3 of 28 patients with del(17p) (11%).”
BackgroundMethodSelf-citationDimopoulos, M. A., Goldschmidt, H., Niesvizky, R., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30578-8 · Cited by 401
Self-citationRichardson, P. G., Oriol, A., Beksac, M., Liberati, A. M., Galli, M., Schjesvold, F., Lindsay, J., Weisel, K., White, D., Facon, T., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30152-4 · Cited by 386
Self-citationFacon, T., Kumar, S. K., Plesner, T., Orlowski, R. Z., Moreau, P., Bahlis, N., Basu, S., Nahi, H., Hulin, C., Quach, H., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00466-6 · Cited by 370
Self-citationMultiple myeloma current treatment algorithms
Rajkumar, S. V., & Kumar, S. K. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-00359-2 · Cited by 373
CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance
van de Donk, N. W. C. J., & Usmani, S. Z. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02134 · Cited by 357
“The median progression-free survival (PFS) and median overall survival (OS) were 4.0 and 20.1 months, respectively.”
BackgroundInfluentialSelf-citationPerna, F., Berman, S., Soni, R. K., Mansilla‐Soto, J., Eyquem, J., Hamieh, M., Hendrickson, R. C., Brennan, C., & Sadelain, M. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.09.004 · Cited by 356
“…non-lineage-restricted, type II transmembrane glycoprotein targeted by Daratumumab, the first U.S. Food and Drug Administration-approved anti-CD38 antibody (Dimopoulos et al., 2016; Lonial et al., 2016) the activity of which on AML is limited without all trans-retinoic acid (Yoshida et al., 2016).”
BackgroundDimopoulos, M. A., Terpos, E., Boccadoro, M., Delimpasi, S., Beksac, M., Katodritou, E., Moreau, P., Baldini, L., Symeonidis, A., Bila, J., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00128-5 · Cited by 344
Self-citationMalard, F., Neri, P. E., Bahlis, N. J., Terpos, E., Moukalled, N. M., Hungria, V., Manier, S., & Mohty, M. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00529-7 · Cited by 387
Self-citationEpidemiology, Staging, and Management of Multiple Myeloma
Padala, S. A., Barsouk, A., Barsouk, A., Rawla, P., Vakiti, A., Kolhe, R., Kota, V., & Ajebo, G. H. (2021) · Medical Sciences · doi:10.3390/medsci9010003 · Cited by 332
“The recently approved monoclonal antibody, daratumumab, which targets CD38 (a re ceptor highly expr sed on myeloma cells), has become a favorite for later line induction regimens [35,36].”
BackgroundTreatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline
Mikhael, J. R., Ismaila, N., Cheung, M. C., Costello, C. L., Dhodapkar, M. V., Kumar, S. K., Lacy, M. Q., Lipe, B. C., Little, R. F., Nikonova, A., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02096 · Cited by 344
“Most clinical trials have used the IMWG criteria for progressive disease, which includes criteria for both biochemical and clinical relapse for initiating therapy.(53,55,58,95,107,112)”
MethodChim, C. S., Kumar, S. K., Orlowski, R. Z., Cook, G., Richardson, P. G., Gertz, M. A., Giralt, S., Mateos, M. V., Leleu, X., & Anderson, K. C. (2018) · Leukemia · doi:10.1038/leu.2017.329 · Cited by 305
Self-citationMeasurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma
Paiva, B., Puig, N., Cedena, M., Rosiñol, L., Cordón, L., Vídriales, M., Burgos, L., Flores-Montero, J. A., Sanoja-Flores, L., López‐Anglada, L., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01231 · Cited by 286
“Persistent MRD 207 (65) 144 (45) 132 (42) MRD log levels $ 10(24) 139 (67) 61 (42) 47 (36) MRD log levels $ 10(25) and , 10(24) 52 (25) 65 (45) 42 (32) MRD log levels $ 2 3 10(26) and 10(25) 16 (8) 18 (13) 43 (32)”
Self-citationMoreau, P., Kumar, S. K., Miguel, J. F. S., Davies, F. E., Zamagni, E., Bahlis, N. J., Ludwig, H., Mikhael, J. R., Terpos, E., Schjesvold, F. H., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30756-7 · Cited by 290
“…disease were rightly excluded from randomised phase 3 trials testing lenalidomide plus dexamethasone versus lenalidomide plus dexamethasone plus a third agent (either a proteasome inhibitor [carfilzomib 11 or ixazomib 12 ] or a monoclonal antibody [elotuzumab 13 or daratumumab 14 ]).”
Self-citationFacon, T., Dimopoulos, M. A., Dispenzieri, A., Catalano, J. V., Belch, A., Cavo, M., Pinto, A., Weisel, K., Ludwig, H., Bahlis, N. J., et al. (2018) · Blood · doi:10.1182/blood-2017-07-795047 · Cited by 271
Self-citationSiegel, D. S. D., Dimopoulos, M. A., Ludwig, H., Facon, T. T. F., Goldschmidt, H., Jakubowiak, A. J., Miguel, J. F. S., Obreja, M., Blædel, J., & Stewart, A. K. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.5032 · Cited by 272
Self-citationCD38-Driven Mitochondrial Trafficking Promotes Bioenergetic Plasticity in Multiple Myeloma
Marlein, C. R., Piddock, R. E., Mistry, J. J., Zaitseva, L., Hellmich, C., Horton, R. H., Zhou, Z., Auger, M. J., Bowles, K. M., & Rushworth, S. A. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-0773 · Cited by 271
“Furthermore, phase III clinical trials in multiple myeloma patients of anti-CD38 antibody therapy given in addition to chemotherapy have demonstrated improvements in overall response rates and progressionfree survival (24, 25) and lower risk of death (26) in patients receiving the antibody with chemotherapy compared w…”
BackgroundSpencer, A. G., Lentzsch, S., Weisel, K. C., Avet‐Loiseau, H., Mark, T. M., Špıčka, I., Masszi, T., Lauri, B., Levin, M., Bosi, A., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.194118 · Cited by 271
“Patients with high-risk cytogenetics had any of t(4;14), t(14;16), or del17p cytogenetic abnormalities as determined by central next-generation sequencing.”
BackgroundInfluentialSelf-citationWu, L., Seung, E., Xu, L., Rao, E., Lord, D. M., Wei, R. R., Cortez‐Retamozo, V., Ospina, B., Posternak, V., Ulinski, G., et al. (2019) · Nature Cancer · doi:10.1038/s43018-019-0004-z · Cited by 273
Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience
Holstein, S. A., & McCarthy, P. L. (2017) · Drugs · doi:10.1007/s40265-017-0689-1 · Cited by 263
“While daratumumab has impressive single agent activity in heavily treated relapsed/refractory patients (overall response rates of 29–36%) [151, 152], recent studies have demonstrated even better activity when combined with either lenalidomide [66, 153] or pomalidomide [85].”
Mateos, M., Nahi, H., Legiec, W. M., Grosicki, S., Vorobyev, V. I., Špıčka, I., Hungria, V., Korenkova, S., Bahlis, N. J., Flogegård, M., et al. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(20)30070-3 · Cited by 259
Self-citationBahlis, N. J., Dimopoulos, M. A., White, D. J., Benboubker, L., Cook, G., Leiba, M., Ho, P. J., Kım, K., Takezako, N., Moreau, P., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0711-6 · Cited by 237
“Statistical analyses have been described previously [12].”
BackgroundResultInfluentialSelf-citationEvolutionary biology of high-risk multiple myeloma
Pawlyn, C., & Morgan, G. J. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2017.63 · Cited by 242
CSG, O. B. O. T. N. H.-O., Shah, V., Sherborne, A. L., Walker, B. A., Johnson, D. C., Boyle, E. M., Ellis, S., Begum, D. B., Proszek, P., Jones, J. R., et al. (2017) · Leukemia · doi:10.1038/leu.2017.179 · Cited by 235
Multiple Myeloma: Available Therapies and Causes of Drug Resistance
Pinto, V., Bergantim, R., Caires, H. R., Seca, H., Guimarães, J. E., & Vasconcelos, M. H. (2020) · Cancers · doi:10.3390/cancers12020407 · Cited by 241
“In relapsed or refractory patients, daratumumab was also approved for triple combinations, either with lenalidomide and dexamethasone [85], bortezomib and dexamethasone [86] or pomalidomide plus dexamethasone [87], showing an important beneficial effect when compared with the same regimens without daratumumab.”
BackgroundResultCasneuf, T., Xu, X. S., Adams, H., Axel, A. E., Chiu, C. W., Khan, I., Ahmadi, T., Yan, X., Lonial, S., Plesner, T., et al. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017006866 · Cited by 231
“39) and substantially improved the response rates in patients with $1 prior lines of therapy.(5,6) On the basis of these results, daratumumab in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, was approved for the treatment of patients with MM who have received $1 prior lines of thera…”
BackgroundSelf-citationInterpreting clinical trial data in multiple myeloma: translating findings to the real-world setting
Richardson, P. G. G., Miguel, J. F. S., Moreau, P., Hájek, R., Dimopoulos, M. A., Laubach, J. P., Palumbo, A. P., Luptakova, K., Romanus, D., Skácel, T., et al. (2018) · Blood Cancer Journal · doi:10.1038/s41408-018-0141-0 · Cited by 236
Self-citationThe Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma
Moreno, L., Pérez, C., Zabaleta, A., Manrique, I., Alignani, D., Ajona, D., Blanco, L., Lasa, M., Maiso, P., Rodríguez, I., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1597 · Cited by 221
“Accordingly, both preclinical (11, 13, 17, 18) and clinical data have confirmed the efficacy of daratumumab in combination with lenalidomide (19, 20) or pomalidomide (21).”
BackgroundSelf-citationCohen, A. D., Mateos, M., Cohen, Y. C., Rodríguez‐Otero, P., Paiva, B., van de Donk, N. W. C. J., Martin, T., Suvannasankha, A., Braganca, K. C. D., Corsale, C., et al. (2022) · Blood · doi:10.1182/blood.2022015526 · Cited by 224
Self-citationImmunotherapy of multiple myeloma
Minnie, S. A., & Hill, G. R. (2020) · Journal of Clinical Investigation · doi:10.1172/jci129205 · Cited by 220
“Daratumumab, a fully human mAb that binds to CD38, also has FDA approval for previously treated myeloma patients after several phase III trials demonstrated strikingly improved outcomes for RRMM patients in the daratumumab arms when it was administered in combination with dexamethasone and lenalidomide (NCT02076009) (…”
BackgroundPalladini, G. O., Kastritis, E., Maurer, M. S., Zonder, J. A., Minnema, M. C., Wechalekar, A. D., Jaccard, A., Lee, H. C., Bumma, N., Kaufman, J. L., et al. (2020) · Blood · doi:10.1182/blood.2019004460 · Cited by 212
Self-citationDimopoulos, M. A., Miguel, J. F. S., Belch, A. R., White, D. J., Benboubker, L., Cook, G., Leiba, M., Morton, J., Ho, P. J., Kım, K., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.194282 · Cited by 213
Self-citationMultiple myeloma: 2018 update on diagnosis, risk‐stratification, and management
Rajkumar, S. V. (2018) · American Journal of Hematology · doi:10.1002/ajh.25117 · Cited by 229
NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018
Kumar, S. K., Callander, N. S., Alsina, M., Atanackovic, D., Biermann, J. S., Castillo, J. J., Chandler, J. C., Costello, C. L., Faiman, M., Fung, H. C. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0002 · Cited by 203
Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies
Davis, J. S., Ferreira, D., Paige, E. K., Gedye, C. A., & Boyle, M. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00035-19 · Cited by 193
“In the POLLUX trial, 569 patients with previously treated multiple myeloma were randomized to daratumumab, dexamethasone, and lenalidomide or dexamethasone and lenalidomide alone (569).”
MethodMoreau, P., Hulin, C., Perrot, A., Arnulf, B., Belhadj, K., Benboubker, L., Béné, M. C., Zweegman, S., Caillon, H., Caillot, D., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00428-9 · Cited by 184
Self-citationMonoclonal antibodies as immunomodulatory therapy against cancer and autoimmune diseases
Hafeez, U., Gan, H. K., & Scott, A. M. (2018) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2018.05.010 · Cited by 182
Turesson, I., Björkholm, M., Blimark, C. H., Kristinsson, S. Y., Vélez, R., & Landgren, O. (2018) · European Journal Of Haematology · doi:10.1111/ejh.13083 · Cited by 188
Krejcik, J., Frerichs, K. A., Nijhof, I. S., van Kessel, B., van Velzen, J. F., Bloem, A. C., Broekmans, M. E. C., Zweegman, S., van Meerloo, J., Musters, R. J. P., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2027 · Cited by 176
“Altogether, this formed the rationale for a phase III study of lenalidomide-dexamethasone with or without daratumumab in relapsed/refractory multiple myeloma, which showed improved outcome for the three-drug compared with the two-drug combination (5).”
BackgroundSelf-citationMartin, T. G., Baz, R., Benson, D. M., Lendvai, N. K., Wolf, J. L., Münster, P. N., Lesokhin, A. M., Wack, C., Charpentier, E., Campana, F., et al. (2017) · Blood · doi:10.1182/blood-2016-09-740787 · Cited by 169
“Stage I 0 1 (33) 4 (17) 6 (50) 5 (36) 16 (28)”
InfluentialTherapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab
Martin, T. G., Corzo, K., Chiron, M., van de Velde, H., Abbadessa, G., Campana, F., Solanki, M., Meng, R., Lee, H., Wiederschain, D., et al. (2019) · Cells · doi:10.3390/cells8121522 · Cited by 166
“gov, NCT02136134) studies, the addition of daratumumab to lenalidomide/dexamethasone or bortezomib/dexamethasone markedly improved the outcome of high-risk patients versus those receiving lenalidomide/dexamethasone or bortezomib/dexamethasone alone [85,86].”
BackgroundAdams, H., Stevenaert, F., Krejcik, J., der Borght, K. V., Smets, T., Bald, J., Abraham, Y., Ceulemans, H., Chiu, C. W., Vanhoof, G., et al. (2018) · Cytometry Part A · doi:10.1002/cyto.a.23693 · Cited by 169
Self-citationDaratumumab in multiple myeloma
Nooka, A. K., Kaufman, J. L., Hofmeister, C. C., Joseph, N. S., Heffner, T. L., Gupta, V. A., Sullivan, H. C., Neish, A. S., Dhodapkar, M. V., & Lonial, S. (2019) · Cancer · doi:10.1002/cncr.32065 · Cited by 166
“Patients with a potentially higher risk of respiratory complications received post-infusion medications, which consisted of diphenhydramine on the first and second days after all infusions, a short-acting β2-adrenergic receptor agonist, and a long-acting bronchodilator such as tiotropium or salmeterol.(15) Given the h…”
BackgroundRelapsed refractory multiple myeloma: a comprehensive overview
Bazarbachi, A. H., Hamed, R. A., Malard, F., Harousseau, J., & Mohty, M. (2019) · Leukemia · doi:10.1038/s41375-019-0561-2 · Cited by 159
Immunotherapy in hematologic malignancies: achievements, challenges and future prospects
Tang, L., Huang, Z., Mei, H., & Hu, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01521-5 · Cited by 181
“It 175 – 179 Ross et al. reported the NK-cell mediated lysis of BCMA-positive MM cell lines induced by AFM26 (anti-BCMA/CD16A bsAb).”
BackgroundModern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes
Landgren, O., & Iskander, K. S. (2017) · Journal of Internal Medicine · doi:10.1111/joim.12590 · Cited by 160
Chimeric antigen receptor–modified T cells: CD19 and the road beyond
Salter, A. I., Pont, M. J., & Riddell, S. R. (2018) · Blood · doi:10.1182/blood-2018-01-785840 · Cited by 166
Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Kumar, S. K., Callander, N. S., Adekola, K., Anderson, L. D., Baljević, M., Baz, R., Campagnaro, E. L., Castillo, J. J., Costello, C. L., D'Angelo, C. R., et al. (2023) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2023.0061 · Cited by 174
Emerging immunotherapies in multiple myeloma
Shah, U. A., & Mailankody, S. (2020) · BMJ · doi:10.1136/bmj.m3176 · Cited by 160
The bone-marrow niche in MDS and MGUS: implications for AML and MM
Ghobrial, I. M., Detappe, A., Anderson, K. C., & Steensma, D. P. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.197 · Cited by 156
Second primary malignancies in multiple myeloma: an overview and IMWG consensus
Musto, P., Anderson, K. C., Attal, M., Richardson, P. G. G., Badros, A., Hou, J., Comenzo, R. L., Du, J., Durie, B. G. M., Miguel, J. F. S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw606 · Cited by 153
Self-citationCombination of flow cytometry and functional imaging for monitoring of residual disease in myeloma
Rasche, L., Alapat, D. V., Kumar, M., Gershner, G. H., McDonald, J., Wardell, C. P., Samant, R., Hemert, R. L. V., Epstein, J., Williams, A. F., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0329-0 · Cited by 157
Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update
Nijhof, I. S., van de Donk, N. W. C. J., Zweegman, S., & Lokhorst, H. M. (2017) · Drugs · doi:10.1007/s40265-017-0841-y · Cited by 146
“Pollux [82] 569 1 (1–11) 93 vs 76 DRd vs Rd NE vs 18.”
BackgroundDimopoulos, M. A., Lonial, S., Betts, K. A., Chen, C. C., Zichlin, M. L., Brun, A., Signorovitch, J., Makenbaeva, D., Mekan, S. F., Sy, O., et al. (2018) · Cancer · doi:10.1002/cncr.31680 · Cited by 142
“Fatigue 154 (48) 32 (10) 130 (41) 26 (8)”
Self-citationTherapy for Relapsed Multiple Myeloma
Dingli, D., Ailawadhi, S., Bergsagel, P. L., Buadi, F. K., Dispenzieri, A. A., Fonseca, R., Gertz, M. A., Gonsalves, W. I., Hayman, S. R., Kapoor, P., et al. (2017) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.01.003 · Cited by 144
“In contrast, for patients who relapse while receiving maintenance therapy with bortezomib or soon after discontinuing bortezomib maintenance, we recommend therapy with daratumumab, lenalidomide, and dexamethasone (DRd).(38,51) It should be noted that disease progression while taking a specific agent does not necessari…”
InfluentialDimopoulos, M. A., Oriol, A., Nahi, H., San-Miguel, J., Bahlis, N. J., Usmani, S. Z., Rabin, N., Orlowski, R. Z., Suzuki, K., Plesner, T., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.00940 · Cited by 140
“0 (1-63) cycles; the median (range) duration of daratumumab monotherapy was 5.”
BackgroundSelf-citationBahlis, N. J., Sutherland, H. J., White, D. J., Sébag, M., Lentzsch, S., Kotb, R. R., Venner, C. P., Gasparetto, C., Col, A. D., Neri, P. E., et al. (2018) · Blood · doi:10.1182/blood-2018-06-858852 · Cited by 139
Self-citationMultiple myeloma: the (r)evolution of current therapy and a glance into future
Gullà, A., & Anderson, K. C. (2020) · Haematologica · doi:10.3324/haematol.2020.247015 · Cited by 143
Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later
Robak, P. J., & Robak, T. (2019) · Drugs in R&D · doi:10.1007/s40268-019-0269-9 · Cited by 147
“…ineligible, untreated 74 91 25 29 24 43 18.1 NR NR NR San-Miguel 2014, 2016 [78, 79] PANORAMA 1 VD vs. Pan VD 381 387 Relapsed and/or refractory 55 61 – – 6 11 8.1 12.0 40.3 35.8 Dimopoulos 2017; 2016 [4, 8] ENDEAVOR KD vs. VD 464 465 Relapsed and/or refractory 77 63 42 22 13 6 18.7…”
InfluentialThanarajasingam, G., Minasian, L. M., Baron, F., Cavalli, F., de Claro, R. A., Dueck, A. C., El‐Galaly, T. C., Everest, N., Geißler, J., Gisselbrecht, C., et al. (2018) · The Lancet Haematology · doi:10.1016/s2352-3026(18)30051-6 · Cited by 140
Self-citationChari, A., Martínez‐López, J., Mateos, M., Bladé, J., Benboubker, L., Oriol, A., Arnulf, B., Rodríguez‐Otero, P., Piñeiro, L., Jakubowiak, A. J., et al. (2019) · Blood · doi:10.1182/blood.2019000722 · Cited by 136
Self-citationDimopoulos, M. A., Lonial, S., White, D. J., Moreau, P., Palumbo, A. P., Miguel, J. F. S., Shpilberg, O., Anderson, K. C., Grosicki, S., Špıčka, I., et al. (2017) · British Journal of Haematology · doi:10.1111/bjh.14787 · Cited by 136
Self-citationImmunoepigenetics Combination Therapies: An Overview of the Role of HDACs in Cancer Immunotherapy
Banik, D., Moufarrij, S., & Villagra, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092241 · Cited by 137
Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide
Jan, M., Sperling, A. S., & Ebert, B. L. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00479-z · Cited by 137
Chen, C. I., Siegel, D. S. D., Gutierrez, M. E., Jacoby, M. A., Hofmeister, C. C., Gabrail, N. Y., Baz, R., Mau‐Sørensen, M., Berdeja, J. G., Savona, M. R., et al. (2017) · Blood · doi:10.1182/blood-2017-08-797886 · Cited by 132
Self-citationZuch de Zafra, C. L., Fajardo, F., Zhong, W., Bernett, M. J., Muchhal, U. S., Moore, G. L., Stevens, J., Case, R., Pearson, J. T., Liu, S., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2752 · Cited by 132
“4%, respectively, in the CASTOR (6) and POLLUX (25) Phase III trials).”
BackgroundInfluentialKararoudi, M. N., Nagai, Y., Elmas, E., Pereira, M. D. S. F., Ali, S. A., Imus, P. H., Wethington, D., Borrello, I., Lee, D. A., & Ghiaur, G. (2020) · Blood · doi:10.1182/blood.2020006200 · Cited by 131
Altaner, Č. (2008) · PubMed · Cited by 130
Sonneveld, P., Chanan-Khan, A. A., Weisel, K. C., Nooka, A. K., Masszi, T., Beksaç, M., Špıčka, I., Hungria, V., Munder, M., Mateos, M., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02734 · Cited by 129
“0 (1-63), and median (range) duration of daratumumab monotherapy was 9.”
BackgroundSelf-citationFacon, T. T. F., Cook, G., Usmani, S. Z., Hulin, C., Kumar, S. K., Plesner, T., Touzeau, C., Bahlis, N. J., Basu, S., Nahi, H., et al. (2022) · Leukemia · doi:10.1038/s41375-021-01488-8 · Cited by 129
Self-citationMechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma
Saltarella, I., Desantis, V., Melaccio, A., Solimando, A. G., Lamanuzzi, A., Ria, R., Storlazzi, C. T., Mariggiò, M. A., Vacca, A., & Frassanito, M. A. (2020) · Cells · doi:10.3390/cells9010167 · Cited by 127
“In phase-three trials (POLLUX and CASTOR), the addition of Dara to standard-of-care regimens proved a higher response rate, depth of response, and PFS in patients with >1 prior lines of therapy [23,24].”
Backgroundvan Beurden-Tan, C. H. Y., Franken, M. G., Blommestein, H. M., Groot, C. A. U., & Sonneveld, P. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.1663 · Cited by 123
Costa, L. J., Derman, B. A., Bal, S., Sidana, S., Chhabra, S., Silbermann, R. W., Ye, J. C., Cook, G., Cornell, R. F., Holstein, S. A., et al. (2020) · Leukemia · doi:10.1038/s41375-020-01012-4 · Cited by 148
“sequent delay in disease progression [55, 56].”
Self-citationWang, Y., Zhang, Y., Hughes, T. L., Zhang, J., Caligiuri, M. A., Benson, D. M., & Yu, J. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3117 · Cited by 124
“NK Healthy donor-no Dara A MM Patient-Dara (1) MM Patient-Dara (2)”
BackgroundInfluentialInfections following bispecific antibodies in myeloma: a systematic review and meta-analysis
Reynolds, G. K., Cliff, E. R. S., Mohyuddin, G. R., Popat, R., Midha, S., Ng, M., Harrison, S. J., Kesselheim, A. S., & Teh, B. W. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023010539 · Cited by 134
“28 Consequently, patients receiving combination therapy including bispeci fi c antibodies should be considered as a higher-risk group requiring further evaluation and targeted prophylaxis.”
BackgroundMultiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up.
Dimopoulos, M. A., Moreau, P., Terpos, E., et al. (2021) · PubMed · doi:10.1097/hs9.0000000000000528 · Cited by 124
Self-citationHilal, T., Sonbol, M. B., & Prasad, V. K. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.0167 · Cited by 123
Casneuf, T., Adams, H., van de Donk, N. W. C. J., Abraham, Y., Bald, J., Vanhoof, G., der Borght, K. V., Smets, T., Foulk, B., Nielsen, K. C., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0855-4 · Cited by 123
Self-citationLandgren, O., Hultcrantz, M. L., Diamond, B. T., Lesokhin, A. M., Mailankody, S., Hassoun, H., Tan, C. R. C., Shah, U. A., Lu, S. X., Salcedo, M., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.0611 · Cited by 120
Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma
Usmani, S. Z., Nahi, H., Mateos, M., van de Donk, N. W. C. J., Chari, A., Kaufman, J. L., Moreau, P., Oriol, A., Plesner, T., Benboubker, L., et al. (2019) · Blood · doi:10.1182/blood.2019000667 · Cited by 120
Self-citation
Metadata
- Authors
- Dimopoulos, M. A., Oriol, A., Nahi, H., San-Miguel, J., Bahlis, N. J., Usmani, S. Z., Rabin, N., Orlowski, R. Z., Komarnicki, M., Suzuki, K., Plesner, T., Yoon, S.-S., Ben Yehuda, D., Richardson, P. G., Goldschmidt, H., Reece, D., Lisby, S., Khokhar, N. Z., O’Rourke, L., Chiu, C., Qin, X., Guckert, M., Ahmadi, T., & Moreau, P.
- Affiliations
- Karolinska University Hospital (SE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-10-06
- Volume
- 375
- Issue
- 14
- Pages
- 1319-1331
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2528329272
- Cited by
- 1,445
- References
- 32
- Citations by year
- 2026: 50 · 2025: 78 · 2024: 78 · 2023: 108 · 2022: 138 · 2021: 221 · 2020: 236 · 2019: 175 · 2018: 193 · 2017: 148 · 2016: 15
- FWCI
- 168.28
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion, other-oa)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- Funders
- Amgen
- Bristol-Myers Squibb
- Spectrum Pharmaceuticals
- Celgene
- Incyte
- Otsuka Pharmaceutical
- Chugai Pharmaceutical
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- daratumumab, lenalidomide, dexamethasone, relapsed/refractory multiple myeloma, progression-free survival, minimal residual disease, complete response, neutropenia, thrombocytopenia, adverse events, monoclonal antibody therapy, combination therapy, overall response rate, safety and tolerability
- MeSH terms
- Lenalidomide, Aged, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Humans, Middle Aged, Multiple Myeloma, Recurrence, Thalidomide, Disease-Free Survival, Drug Resistance, Neoplasm, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
